Evidence map›Paper›PMID 38743077›Full record

ArticleMolecular genetics and genomics : MGG2024

EMP1 correlated with cancer progression and immune characteristics in pan-cancer and ovarian cancer.

Jun Zhang, Jing Yang, Xing Li, Lin Mao, Yan Zhang, Yi Liu, Yindi Bao

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular genetics and genomics : MGG, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Bioinformatic Approach to Identify PotentialInternational journal of molecular sciences · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jun ZhangDepartment of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.
Jing YangDepartment of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.
Xing LiDepartment of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.
Lin MaoDepartment of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.
Yan ZhangDepartment of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.
Yi LiuDepartment of Obstetrics and Gynecology, Xiaogan Central Hospital, Xiaogan, Hubei, China.
Yindi BaoDepartment of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan, Hubei, China. rm003478@whu.edu.cn.ORCID http://orcid.org/0009-0006-7017-7540

Funding

Key Technology Research and Development Program of Shandong Province 2018YFC1002804National Key Research and Development Program of China 2016YFC1000600National Natural Science Foundation of China 81771618National Natural Science Foundation of China 81971356
6 · The paper itself

Abstract

This study examines the prognostic role and immunological relevance of EMP1 (epithelial membrane protein-1) in a pan-cancer analysis, with a focus on ovarian cancer. Utilizing data from TCGA, CCLE, and GTEx databases, we assessed EMP1 mRNA expression and its correlation with tumor progression, prognosis, and immune microenvironment across various cancers. Our results indicate that EMP1 expression is significantly associated with poor prognosis in multiple cancer types, including ovarian, bladder, testicular, pancreatic, breast, brain, and uveal melanoma. Immune-related analyses reveal a positive correlation between EMP1 and immune cell infiltration, particularly neutrophils, macrophages, and dendritic cells, as well as high expression of immune checkpoint such as CD274, HAVCR2, IL10, PDCD1LG2, and TGFB1 in most tumors. In vivo experiments confirm that EMP1 promotes ovarian cancer cell proliferation, metastasis, and invasion. In conclusion, EMP1 emerges as a potential prognostic biomarker and therapeutic target in various cancers, particularly ovarian cancer, due to its influence on tumor progression and immune cell dynamics. Further research is warranted to elucidate the precise mechanisms of EMP1 in cancer biology and to translate these findings into clinical applications.

Indexed as

Disease ProgressionOvarian NeoplasmsAnimalsBiomarkers, TumorCell Line, TumorCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansMembrane GlycoproteinsMiceNeoplasmsPrognosisTumor MicroenvironmentBiomarkers, TumorMembrane GlycoproteinsEMP1Immune infiltrationOvarian cancerPan-cancerThe Cancer Genome Atlas

Identifiers

PMID38743077

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.